Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guizhou Yibai Pharmaceutical Co., Ltd. (600594.SS)
Guiyang, CN
Guizhou Yibai Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that encompasses the full spectrum of activities from researching and developing new drugs to their production and commercialization throughout the country. The company offers a diverse portfolio of medications, available in various dosage forms including capsules, tablets, granules, syrups, liquid injectables (small-volume), lyophilized powder injections, traditional pills, and oral solutions. These therapeutic agents are designed to address a broad range of medical conditions, specifically targeting oncology, cerebrovascular health, respiratory ailments, rheumatic diseases, digestive disorders, pediatric and gynecological illnesses, alongside providing anti-infective, anti-inflammatory, and pain management solutions. Established in 1995, the company maintains its headquarters in Guiyang, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.28% | -5.35% | -12.59% | -13.87% | -16.31% | -11.06% | -10.15% | -41.87% | -41.58% | -76.27% | +81.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-14.9% Q1'26: -28.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-5.0% Q1'26: -213.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.7% Q1'26: +10.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-8.0% Q1'26: -6.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-5.8% Q1'26: -3.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.6% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×16.66× Q1'26: -7.93× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
3.30B
est: 3.69B (-10.5%)
|
3.69B
est: 3.90B (-5.3%)
|
3.81B
est: 4.11B (-7.3%)
|
3.88B
est: 3.71B (+4.6%)
|
3.36B
est: 3.32B (+1.3%)
|
3.41B
est: 3.34B (+2.3%)
|
3.35B
est: 3.41B (-1.8%)
|
| EBITDA |
371.02M
est: 256.81M (+44.5%)
|
659.54M
est: 271.16M (+143.2%)
|
708.59M
est: 286.01M (+147.8%)
|
-530.61M
est: 258.45M (-305.3%)
|
413.03M
est: 231.00M (+78.8%)
|
483.93M
est: 232.30M (+108.3%)
|
495.78M
est: 237.14M (+109.1%)
|
| EBIT |
284.80M
est: -6.48M (+4,493.6%)
|
546.76M
est: -6.84M (+8,088.7%)
|
570.00M
est: -7.22M (+7,995.9%)
|
-709.93M
est: -6.52M (-10,782.7%)
|
260.43M
est: -5.83M (+4,566.6%)
|
343.03M
est: -5.86M (+5,950.4%)
|
348.22M
est: -5.99M (+5,917.8%)
|
| Net Income |
189.38M
est: 319.78M (-40.8%)
|
384.86M
est: 413.24M (-6.9%)
|
387.53M
est: 404.03M (-4.1%)
|
-725.50M
est: -795.41M (+8.8%)
|
141.90M
est: 247.73M (-42.7%)
|
228.76M
est: 261.38M (-12.5%)
|
243.77M
est: 279.62M (-12.8%)
|
| SGA |
2.33B
est: 1.83B (+26.8%)
|
2.20B
est: 1.94B (+13.7%)
|
2.19B
est: 2.04B (+7.3%)
|
2.34B
est: 1.85B (+26.7%)
|
2.16B
est: 1.65B (+30.6%)
|
2.04B
est: 1.66B (+23.1%)
|
1.98B
est: 1.69B (+16.8%)
|
| EPS |
0.24
est: 0.41 (-40.8%)
|
0.49
est: 0.52 (-6.4%)
|
0.49
est: 0.51 (-4.3%)
|
-0.92
est: -1.01 (+8.7%)
|
0.18
est: 0.31 (-42.7%)
|
0.29
est: 0.33 (-12.5%)
|
0.31
est: 0.35 (-12.5%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 1.1K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 2.4K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 118.8K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 191.07 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 575.21 | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 309.42 | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 136.38 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 15.73 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 5.16 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 2.46 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hua Wen Wang | Deputy General Manager | — | male |
| Jian Pu | Deputy General Manager | — | female |
| Jiang Xianhong | Deputy GM & Secretary to the Board | — | male |
| Li Dong Wang | Deputy General Manager | — | male |
| Xianti Zeng | Financial Director | — | male |
| Ya Qi Dou | Vice Chairman, Accounting Supervisor & Deputy GM | — | female |
| Zhiwei Wang | Deputy GM & Director | — | male |
| Zhou Yi | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600594.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
